← Leaderboards
Alejandro V Villagra
Georgetown University
$1,948,655
Attributed
$3,954,084
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $618.6K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,954,084 · 4
By mechanism
R01$2,951,398 · 1
R21$802,685 · 2
R41$200,001 · 1
Top collaborators
- Duncan John Wardrop6 shared
- Cyril Barinka5 shared
- Rohan Fernandes1 shared
- Elizabeth E Sweeney1 shared
Most similar at Georgetown University
Same institution · by research overlap
- Duncan John Wardrop$3,076,392
- Anton Wellstein$12,396,274
- Cyril Barinka$792,791
- Sarah Martinez Roth$100,677
- Hyang-Sook Hoe$548,936
Others in their field
Top investigators on “Attention”
- David R. Weir · University Of Michigan At Ann Arbor$240,842,195
- Richard K. Wilson · Washington University$202,137,538
- Maury Tigner · Cornell University$99,355,712
- Lee Marshall Nadler · Dana-Farber Cancer Inst$89,956,287
- Richard A Gibbs · Baylor College Of Medicine$71,884,371
- Jeffrey P Krischer · University Of South Florida$57,407,902
Research focus
AttentionHdac6 GeneTumorEpigenetic ProcessInterleukin-10ProteinsReportingImmuneMalignant NeoplasmsCytokineIn VitroMediatingIn VivoImmunoregulationHistone Deacetylase InhibitorInflammatoryGeneticAnti-Inflammatory AgentsDeacetylaseBlocking AntibodiesCellsImmune SystemCancer ImmunotherapyCharacteristics
Grant awards (12)
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$573,024
R01 · FY2025 · CA · contact PI
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$567,683
R01 · FY2024 · CA · contact PI
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$605,710
R01 · FY2023 · CA · contact PI
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$514,297
R01 · FY2022 · CA · contact PI
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$104,326
R01 · FY2022 · CA · contact PI
Development of selective HDAC6 inhibitors to improve cancer immunotherapy$586,358
R01 · FY2021 · CA · contact PI
An Engineered Nanoimmunotherapy for Melanoma$200,001
R41 · FY2018 · CA
Role of HDAC6 in the modulation of Immune-related pathways in Melanoma$148,053
R21 · FY2015 · CA · contact PI
Role of HDAC6 in the modulation of Immune-related pathways in Melanoma$71,840
R21 · FY2015 · CA · contact PI
Role of HDAC6 in the modulation of Immune-related pathways in Melanoma$183,244
R21 · FY2014 · CA · contact PI
Role of Histone Deacetylases 6 and 11 in regulation of IL-10 and immune responses$217,935
R21 · FY2012 · CA · contact PI
Role of Histone Deacetylases 6 and 11 in regulation of IL-10 and immune responses$181,613
R21 · FY2011 · CA · contact PI